Metformin, a clinically used AMPK agonist for diabetes, or rapamycin, a specific mTOR inhibitor, inhibits KOA synovial inflammation by increasing phosphorylation of AMPK or inhibiting phosphorylation of mTOR, respectively [14, 15]. Here, MTOR is linked to diabetes mellitus.